MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis
- PMID: 17263005
- DOI: 10.1177/1352458506070775
MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis
Abstract
Observational cohort studies are a powerful tool to assess the long-term outcome in chronic diseases. This study design has been utilized in local and regional outcome studies in multiple sclerosis (MS) and has yielded invaluable epidemiological information. The World Wide Web now provides an excellent opportunity for an international, collaborative cohort study of MS outcomes. A web platform--MSBase--has been designed to collect prospective data on patients with MS. It is purely observational, enabling participating neurologists to contribute data on diagnosis, treatment and progress, to review anonymous aggregate data and to benchmark their patient population against other patient subsets or the entire dataset. MSBase facilitates collaborative research by allowing the online creation of investigator-initiated regional, national and international substudies. The registry aims to answer epidemiological questions that can only be addressed by prospective assessments of large patient cohorts. The registry is funded through the independent MSBase Foundation, and governed by an International Scientific Advisory Board. The MSBase Foundation commenced operations in July 2004 and since then, 22 neurologists from 11 countries have joined MSBase and are contributing 2400 patients to the total data pool.
Similar articles
-
A need for national registries and international collaborative research in multiple sclerosis.Acta Neurol Scand Suppl. 2012;(195):1-3. doi: 10.1111/ane.12039. Acta Neurol Scand Suppl. 2012. PMID: 23278648
-
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.Lancet Neurol. 2020 Apr;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18. Lancet Neurol. 2020. PMID: 32199096
-
The MSBase registry: Informing clinical practice.Mult Scler. 2019 Dec;25(14):1828-1834. doi: 10.1177/1352458519848965. Epub 2019 May 23. Mult Scler. 2019. PMID: 31120376 Review.
-
Can databasing optimise patient care?J Neurol. 2004 Sep;251 Suppl 5:v79-v82. doi: 10.1007/s00415-004-1513-x. J Neurol. 2004. PMID: 15549361
-
From the Gothenburg cohort to the Swedish multiple sclerosis registry.Acta Neurol Scand Suppl. 2012;(195):13-9. doi: 10.1111/ane.12023. Acta Neurol Scand Suppl. 2012. PMID: 23278651 Review.
Cited by
-
The importance of collecting structured clinical information on multiple sclerosis.BMC Med. 2016 May 31;14:81. doi: 10.1186/s12916-016-0627-1. BMC Med. 2016. PMID: 27246898 Free PMC article.
-
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosis.PLoS One. 2013 May 21;8(5):e63480. doi: 10.1371/journal.pone.0063480. Print 2013. PLoS One. 2013. PMID: 23704913 Free PMC article. Clinical Trial.
-
COVID-19 vaccination uptake in people with multiple sclerosis compared to the general population.Acta Neurol Belg. 2023 Dec;123(6):2269-2275. doi: 10.1007/s13760-023-02296-w. Epub 2023 Jun 1. Acta Neurol Belg. 2023. PMID: 37261658 Free PMC article.
-
From real world data to real world evidence to improve outcomes in neuro-ophthalmology.Eye (Lond). 2024 Aug;38(12):2448-2456. doi: 10.1038/s41433-024-03160-8. Epub 2024 Jun 6. Eye (Lond). 2024. PMID: 38844583 Free PMC article. Review.
-
Multiple Sclerosis Relapses Following Cessation of Fingolimod.Clin Drug Investig. 2022 Apr;42(4):355-364. doi: 10.1007/s40261-022-01129-7. Epub 2022 Mar 18. Clin Drug Investig. 2022. PMID: 35303292 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical